» Articles » PMID: 9454774

Antimalarial Activity of 77 Phospholipid Polar Head Analogs: Close Correlation Between Inhibition of Phospholipid Metabolism and in Vitro Plasmodium Falciparum Growth

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1998 Mar 7
PMID 9454774
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Seventy-seven potential analogs of phospholipid polar heads, choline and ethanolamine, were evaluated in vitro as inhibitors of Plasmodium falciparum growth. Their IC50 ranged from 10(-3) to 10(-7) mol/L. Ten compounds showed similar antimalarial activity when tested against three different parasite strains (2 chloroquine-sensitive strains and 1 chloroquine-resistant strain). Compounds showing marked antimalarial activity were assayed for their effects on phospholipid metabolism. The most active compounds (IC50 of 1 to 0.03 micromol/L) were inhibitors of de novo phosphatidylcholine (PC) biosynthesis from choline. For a series of 50 compounds, there was a close correlation between impairment of phospholipid biosynthesis and inhibition of in vitro malaria parasite growth. High choline concentrations caused a marked specific shift in the curves for PC biosynthesis inhibition. Concentrations inhibiting 50% PC metabolism from choline were in close agreement with the Ki of these compounds for the choline transporter in Plasmodium knowlesi-infected erythrocytes. By contrast, measurement of the effects of 12 of these compounds on rapidly dividing lymphoblastoid cells showed a total absence of correlation between parasite growth inhibition and human lymphoblastoid cell growth inhibition. Specific antimalarial effects of choline or ethanolamine analogs are thus likely mediated by their alteration of phospholipid metabolism. This indicates that de novo PC biosynthesis from choline is a very realistic target for new malaria chemotherapy, even against pharmacoresistant strains.

Citing Articles

Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments.

Mustiere R, Vanelle P, Primas N Molecules. 2020; 25(24).

PMID: 33334080 PMC: 7765515. DOI: 10.3390/molecules25245949.


ChoK-ing the Pathogenic Bacteria: Potential of Human Choline Kinase Inhibitors as Antimicrobial Agents.

Khalifa M, Few L, See Too W Biomed Res Int. 2020; 2020:1823485.

PMID: 32695809 PMC: 7368946. DOI: 10.1155/2020/1823485.


Recent updates in the discovery and development of novel antimalarial drug candidates.

Okombo J, Chibale K Medchemcomm. 2018; 9(3):437-453.

PMID: 30108934 PMC: 6071755. DOI: 10.1039/c7md00637c.


High Accumulation and Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death.

Wein S, Taudon N, Maynadier M, Van Ba C, Margout D, Bordat Y Antimicrob Agents Chemother. 2017; 61(8).

PMID: 28607017 PMC: 5527631. DOI: 10.1128/AAC.00352-17.


An Atypical Mitochondrial Carrier That Mediates Drug Action in Trypanosoma brucei.

de Macedo J, Schumann Burkard G, Niemann M, Barrett M, Vial H, Maser P PLoS Pathog. 2015; 11(5):e1004875.

PMID: 25946070 PMC: 4422618. DOI: 10.1371/journal.ppat.1004875.